Impact of a Fixed-Dose Combination of Naproxen and Esomeprazole Magnesium on Serum Thromboxane B 2 Inhibition by Low-Dose Aspirin Over 5 Days in Healthy Adults: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Noninferiority Trial

Clinical Therapeutics

Volumn 33, Issue 12, 2011, Pages 1883-1893

  Angiolillo, Dominick J ^a   Hwang, Clara ^b   Datto, Catherine ^b   Desai, Bhaloo ^a   Sostek, Mark ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Aspirin; Esomeprazole; Naproxen; Platelets; Thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; ESOMEPRAZOLE PLUS NAPROXEN; PLACEBO; THROMBOXANE B2;

ADULT; AGED; ARTICLE; BACKACHE; BLOOD LEVEL; BLOOD PRESSURE; BLOOD PRESSURE FLUCTUATION; CHLAMYDIAL URETHRITIS; CONSTIPATION; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSGEUSIA; ENZYME INHIBITION; EPISTAXIS; EVENING DOSAGE; EXCORIATION; EYE INFECTION; FEMALE; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; LOW DRUG DOSE; MALE; MORNING DOSAGE; NORMAL HUMAN; NOSE CONGESTION; OROPHARYNGEAL PAIN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN ABRASION; SORE THROAT; THROAT IRRITATION; VITAL SIGN;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD PLATELETS; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NAPROXEN; OMEPRAZOLE; PILOT PROJECTS; PLACEBOS; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; TABLETS, ENTERIC-COATED; THROMBOXANE B2; TIME FACTORS; UNITED STATES;

EID: 83455196215     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.10.009     Document Type: Article

References (48)

1. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001, 120:594-606.
2. Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther 2000, 7:115-121.
3. Zhang W., Doherty M., Arden N., et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005, 64:669-681.
4. Zhang W., Moskowitz R.W., Nuki G., et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162.
5. Desai S.P., Solomon D.H., Abramson S.P., et al. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum 2008, 59:1058-1073.
6. The care and management of osteoarthritis in adults. NICE clinical guideline 59, 2008 National Institute for Health and Clinical Excellence, Accessed December 17, 2010. http://www.nice.org.uk/nicemedia/pdf/CG59NICEguideline.pdf.
7. Ajani U.A., Ford E.S., Greenland K.J., et al. Aspirin use among U.S. adults: behavioral risk factor surveillance system. Am J Prev Med 2006, 30:74-77.
8. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86. Antithrombotic Trialists' Collaboration.
9. Sopena F., Lanas A. How to advise aspirin use in patients who need NSAIDs. Curr Pharm Des 2007, 13:2248-2260.
10. Vane J.R., Botting R.M. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998, 104(Suppl 3A):2S-8S.
11. Corman S.L., Fedutes B.A., Ansani N.T. Impact of nonsteroidal antiinflammatory drugs on the cardioprotective effects of aspirin. Ann Pharmacother 2005, 39:1073-1079.
12. Patrono C., García-Rodríguez L.A., Landolfi R., Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005, 353:2373-2383.
13. Catella-Lawson F., Reilly M.P., Kapoor S.C., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001, 345:1809-1817.
14. Kearney P.M., Baigent C., Godwin J., et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006, 332:1302-1308.
15. Trelle S., Reichenbach S., Wandel S., et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011, 342:c7086.
16. Rahme E., Nedjar H., Bizzi A., Morin S. Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study. Aliment Pharmacol Ther 2007, 26:1387-1398.
17. Lanas A., García-Rodríguez L.A., Arroyo M.T., et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006, 55:1731-1738.
18. Lanza F.L., Chan F.K., Quigley E.M.M. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009, 104:728-738.
19. Scheiman J.M., Fendrick A.M. Summing the risk of NSAID therapy. Lancet 2007, 369:1580-1581.
20. Jung D., Schwartz K.E. Steady-state pharmacokinetics of enteric-coated naproxen tablets compared with standard naproxen tablets. Clin Ther 1994, 16:923-929.
21. Miner P., Plachetka J., Orlemans E., et al. Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomised, open-label, Phase I study in healthy volunteers. Aliment Pharmacol Ther 2010, 32:414-424.
22. VIMOVO prescribing information, 2010 Food and Drug Administration (FDA), Accessed December 17, 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022511lbl.pdf.
23. Summary of Product Characteristics. VIMOVO 500 mg/20 mg modified-release tablets, 2010 Electronic Medicines Compendium (eMC), Accessed December 17, 2010. http://www.medicines.org.uk/EMC/medicine/23883/SPC/VIMOVO+500+mg+20+mg+modified-release+tablets.
24. 2. Curr Med Res Opin 2010, 26:1497-1504.
25. Kyrle P.A., Minar E., Brenner B., et al. Thromboxane A2 and prostacyclin generation in the microvasculature of patients with atherosclerosis-effect of low-dose aspirin. Thromb Haemost 1989, 61:374-377.
26. Patrono C., Ciabattoni G., Pinca E., et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980, 17:317-327.
27. Concomitant use of ibuprofen and aspirin: potential for attenuation of the anti-platelet effect of aspirin. Food and Drug Administration Science Paper, 2006 Food and Drug Administration (FDA), Accessed December 17, 2010. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM161282.pdf.
28. Capone M.L., Sciulli M.G., Tacconelli S., et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005, 45:1295-1301.
29. Galliard-Grigioni K.S., Reinhart W.H. A randomized, controlled study on the influence of acetaminophen, diclofenac, or naproxen on aspirin-induced inhibition of platelet aggregation. Eur J Pharmacol 2009, 609:96-99.
30. Gladding P.A., Webster M.W.I., Farrell H.B., et al. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 2008, 101:1060-1063.
31. Anzellotti P., Capone M.L., Jeyam A., et al. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum 2011, 63:850-859.
32. Capone M.L., Tacconelli S., Sciulli M.G., et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004, 109:1468-1471.
33. Abraham N.S., El-Serag H.B., Johnson M.L., et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 2005, 129:1171-1178.
34. Sturkenboom M.C.J.M., Burke T.A., Dieleman J.P., et al. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 2003, 42(Suppl 3):iii23-iii31.
35. Goldstein J.L., Howard K.B., Walton S.M., et al. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006, 4:1337-1345.
36. Sturkenboom M.C.J.M., Burke T.A., Tangelder M.J.D., et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003, 18:1137-1147.
37. van Soest E.M., Sturkenboom M.C.J.M., Dieleman J.P., et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 2007, 26:265-275.
38. Hochberg M., Cryer B., Fort J.G., et al. A fixed-dose combination of naproxen and esomeprazole magnesium (VIMOVO) has comparable efficacy and tolerability to celecoxib in patients with osteoarthritis (OA) of the knee: results from two randomized, controlled trials (abstract). Arthritis Rheum. 2010, 62(Suppl 10):S388.
39. Goldstein J.L., Hochberg M.C., Fort J.G., et al. Clinical trial: incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther 2010, 32:401-413.
40. Schiff M., Hochberg M.C., Oldenhof J., Brune K. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. Curr Med Res Opin 2009, 25:2471-2477.
41. Van Hecken A., Schwartz J.I., Depré M., et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000, 40:1109-1120.
42. Würtz M., Grove E.L., Kristensen S.D., Hvas A.-M. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart 2010, 96:368-371.
43. Adamopoulos A.B., Sakizlis G.N., Nasothimiou E.G., et al. Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study. J Cardiovasc Pharmacol 2009, 54:163-168.
44. Inarrea P., Esteva F., Cornudella R., Lanas A. Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man. Scand J Gastroenterol 2000, 35:242-246.
45. Kasprzak M., Kozinski M., Bielis L., et al. Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. Cardiol J 2009, 16:535-544.
46. Nefesoglu F.Z., Yanoglu-Dulger G., Ulusoy N.B., Imeryuz N. Interaction of omeprazole with enteric-coated salicylate tablets. Int J Clin Pharmacol Ther 1998, 36:549-553.
47. Niazi M., Andersson T., Naucler E., et al. Evaluation of the pharmacokinetic interaction between esomeprazole (40 mg) and acetylsalicylic acid (325 mg) in healthy volunteers. Int J Clin Pharmacol Ther 2009, 47:564-569.
48. Frelinger A.L., Li Y., Linden M.D., et al. Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost 2008, 6:2035-2044.